Gilead dispels doubts with Car-T cancer drug trial results – Financial Times
Financial Times |
Gilead dispels doubts with Car–T cancer drug trial results
Financial Times A pioneering cancer treatment being developed by the US biotech company Gilead Sciences can keep some of the sickest lymphoma patients alive for at least a year, according to the results of a much-anticipated clinical trial published on Sunday. The … ASH17: Benefit of Gilead's CAR–T remains durable over longer term Gilead's new drug keeps 56 percent of lymphoma trial patients alive Look back at pharma news to Dec 8 |
